Skip to main content
¿Habla español?
Comuníquese con nuestra mesa de ayuda 24/7/365 al 877-635-9545.
Young businesswoman using a digital tablet while standing in front of windows in office Young businesswoman using a digital tablet while standing in front of windows in office Young businesswoman using a digital tablet while standing in front of windows in office

ProAct
Resources

 

Lower Costs and Expanded Access for Inflammatory Conditions with New Biosimilars

Lower Costs and Expanded Access for Inflammatory Conditions with New Biosimilars hero image

At ProAct, we continue to enable affordable access to biosimilars and help ensure a smooth transition for patients starting these innovative products. Our thoughtful and comprehensive approach to include inflammatory biosimilars on our ...

Johnson & Johnson's Tremfya® Receives FDA Approval

Johnson & Johnson's Tremfya® Receives FDA Approval hero image

On March 20, 2025, Johnson & Johnson’s Tremfya® (guselkumab) received FDA approval for a label expansion for the treatment of Crohn’s Disease (CD). Tremfya® is the first and only interleukin (IL)-23 inhibitor offering both subcutaneous ...

Eli Lilly's New Oral Weight Loss Medication Has Shown Promising Results

Eli Lilly's New Oral Weight Loss Medication Has Shown Promising Results hero image

A new oral weight loss medication by Eli Lilly, Orforglipron, showed promising results in a phase 2 trial published in the New England Journal of Medicine in June 2023. The highest dose of the drug resulted in approximately 15% weight loss ...

First Xolair Biosimilar Approved, But Not Yet Launched

First Xolair Biosimilar Approved, But Not Yet Launched hero image

On March 7, 2025, the US Food and Drug Administration (FDA) approved Celltrion’s Omlyclo® (omalizumab-igec) as the first interchangeable biosimilar to Novartis’ Xolair® (omalizumab). Omlyclo is approved for the same indications as ...

FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize

FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize hero image

The US Food and Drug Administration (FDA) has determined the shortage of glucagon-like peptide 1 (GLP-1) medication, semaglutide, is resolved. Semaglutide injection products have been on the FDA shortage list since 2022. The FDA ...

ProAct Logo ProAct Logo ProAct Logo
mobile image tablet image desktop image